Halozyme Therapeutics reported second-quarter revenue of $481 million, beating analyst estimates by 19% and growing 47.7% year over year, driven by record royalty growth from its ENHANZE platform. Adjusted EPS of $2.28 beat estimates by 25.5%, and the company raised full-year revenue guidance to $1.87 billion at the midpoint, a 6.4% increase. During the earnings call, analysts focused on royalty revenue acceleration, target exclusivity, Hypercon pipeline launches, deal cadence, and Merck litigation. CEO Helen Torley highlighted that five to seven product launches by the mid-2030s underpin a $1 billion royalty target, with both new and existing partner deals contributing.
Halozyme Therapeutics IncQ2 revenue and EPS beat estimates, and full-year guidance raised.
